Complete response of metastasized adrenal cortical carcinoma with o,p'-ddd.Case report and literature review
- 1 January 1984
Abstract
This study concerns the history of a male patient with hormone‐producing adrenal cortical carcinoma. Six months after resection of the primary tumor, lymph node metastases were detected and treatment with o,p'‐DDD[1,1 dichloro‐2‐(o‐chlorophenyl)‐2‐(p‐chlorophenyl)ethane] (Lysodren/mitotane) was started. After 2 years, a complete histologically proven response was confirmed at laparotomy and is still sustained 2 years after the discontinuation of treatment. As a consequence of insufficient steroid replacement the patient suffered bouts of adrenal insufficiency. After 1 year of treatment, the measurement of the plasma levels of o,p'‐DDD showed an accumulation of the drug. At that time, progressive major central nervous system toxicity occurred, which proved to be reversible on discontinuation of the treatment. Cancer 53:26‐29, 1984.This publication has 17 references indexed in Scilit:
- Metastatic Adrenal Cortical CarcinomaJAMA, 1981
- Natural history of adrenal cortical carcinoma: A clinicopathologic study of 42 patientsCancer, 1981
- Adrenal adenocarcinomas: Diagnosis and managementJournal of Surgical Oncology, 1981
- Mitotane (o, p′-DDD)Cancer Treatment Reviews, 1980
- o,p′-DDD (mitotane) therapy of adrenal cortical carcinoma. Observations on drug dosage, toxicity, and steroid replacementCancer, 1978
- Metastatic Adrenal Cortical CarcinomaArchives of Internal Medicine, 1975
- o,p'DDD Therapy in Invasive Adrenocortical CarcinomaAnnals of Internal Medicine, 1975
- Adrenal cortical carcinomaAmerican Journal Of Medicine, 1966
- Addison's Disease Following Combined Chemotherapy for Hyperfunctioning Adrenocortical CarcinomaArchives of Internal Medicine, 1966
- CHEMOTHERAPY OF ADRENOCORTICAL CANCER WITH o,p′DDDAnnals of Internal Medicine, 1960